Xilio Therapeutics (NASDAQ:XLO) Downgraded to Hold Rating by Wall Street Zen
by Teresa Graham · The Cerbat GemWall Street Zen cut shares of Xilio Therapeutics (NASDAQ:XLO – Free Report) from a buy rating to a hold rating in a report released on Saturday.
Separately, Weiss Ratings upgraded shares of Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Xilio Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.
Read Our Latest Stock Report on Xilio Therapeutics
Xilio Therapeutics Trading Down 5.1%
XLO stock opened at $8.36 on Friday. The company has a market cap of $49.99 million, a price-to-earnings ratio of -2.35 and a beta of -0.16. Xilio Therapeutics has a 12 month low of $6.47 and a 12 month high of $16.10. The firm has a 50-day moving average of $8.11 and a two-hundred day moving average of $8.95.
Xilio Therapeutics (NASDAQ:XLO – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.08. The company had revenue of $12.65 million during the quarter, compared to the consensus estimate of $8.52 million. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%. As a group, equities analysts forecast that Xilio Therapeutics will post -2.39 earnings per share for the current year.
Hedge Funds Weigh In On Xilio Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its position in Xilio Therapeutics by 13.7% in the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after buying an additional 22,500 shares during the period. Jane Street Group LLC purchased a new position in Xilio Therapeutics in the 4th quarter valued at approximately $27,000. Squarepoint Ops LLC boosted its position in Xilio Therapeutics by 39.6% in the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after buying an additional 93,338 shares during the period. Renaissance Technologies LLC boosted its position in Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after buying an additional 139,716 shares during the period. Finally, Velan Capital Investment Management LP purchased a new position in Xilio Therapeutics in the 4th quarter valued at approximately $109,000. Hedge funds and other institutional investors own 54.29% of the company’s stock.
About Xilio Therapeutics
Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.
The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.